Amgen's Neulasta gains another biosimilar competitor as sales slip

Neulasta, one of Amgen’s oldest drug franchises, has another biosimilar to contend with.

German pharma Fresenius Kabi announced on Tuesday that the FDA has approved its pegfilgrastim biosimilar, to be marketed as Stimufend.